These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 1669831)

  • 1. Measurement of aromatisation by a urine technique suitable for the evaluation of aromatase inhibitors in vivo.
    Jacobs S; Lønning PE; Haynes B; Griggs L; Dowsett M
    J Enzyme Inhib; 1991; 4(4):315-25. PubMed ID: 1669831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer.
    MacNeill FA; Jones AL; Jacobs S; Lønning PE; Powles TJ; Dowsett M
    Br J Cancer; 1992 Oct; 66(4):692-7. PubMed ID: 1419608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective inhibition by low dose aminoglutethimide of peripheral aromatization in postmenopausal breast cancer patients.
    Dowsett M; Santner SJ; Santen RJ; Jeffcoate SL; Smith IE
    Br J Cancer; 1985 Jul; 52(1):31-5. PubMed ID: 4015950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients.
    Jones AL; MacNeill F; Jacobs S; Lonning PE; Dowsett M; Powles TJ
    Eur J Cancer; 1992; 28A(10):1712-6. PubMed ID: 1389491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of CGS 16949A on peripheral aromatisation in breast cancer patients.
    Lønning PE; Jacobs S; Jones A; Haynes B; Powles T; Dowsett M
    Br J Cancer; 1991 May; 63(5):789-93. PubMed ID: 1828173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aromatase inhibitors for treatment of breast cancer: current concepts and new perspectives.
    Santen RJ
    Breast Cancer Res Treat; 1986; 7 Suppl():S23-35. PubMed ID: 3527304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Local endocrine effects of aromatase inhibitors within the breast.
    Miller WR; Dixon JM
    J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):93-102. PubMed ID: 11850212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors.
    Lønning PE; Haynes BP; Dowsett M
    Eur J Cancer; 2014 Apr; 50(6):1055-64. PubMed ID: 24507547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients.
    Geisler J; King N; Anker G; Ornati G; Di Salle E; Lønning PE; Dowsett M
    Clin Cancer Res; 1998 Sep; 4(9):2089-93. PubMed ID: 9748124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer.
    Miller WR; Stuart M; Sahmoud T; Dixon JM
    Br J Cancer; 2002 Oct; 87(9):950-5. PubMed ID: 12434282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression.
    MacNeill FA; Jacobs S; Lønning PE; Powles TJ; Dowsett M
    Br J Cancer; 1994 Jun; 69(6):1171-5. PubMed ID: 8198987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aromatisation of androstenedione by human breast cancer tissue: correlation with hormone receptor activity and possible biologic significance.
    Bezwoda WR; Mansoor N; Dansey R; Esser JD
    Oncology; 1987; 44(1):30-3. PubMed ID: 3561925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations in the metabolism of oestrogens during treatment with aminoglutethimide in breast cancer patients. Preliminary findings.
    Lønning PE; Kvinnsland S; Thorsen T; Ueland PM
    Clin Pharmacokinet; 1987 Dec; 13(6):393-406. PubMed ID: 3436111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In situ oestrone synthesis in normal breast and breast tumour tissues: effect of treatment with 4-hydroxyandrostenedione.
    Reed MJ; Owen AM; Lai LC; Coldham NG; Ghilchik MW; Shaikh NA; James VH
    Int J Cancer; 1989 Aug; 44(2):233-7. PubMed ID: 2759729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: clinical and endocrine effects.
    Geisler J; Johannessen DC; Anker G; Lønning PE
    Eur J Cancer; 1996 May; 32A(5):789-92. PubMed ID: 9081355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aminoglutethimide--a new endocrine therapy in breast cancer. A cancer research review.
    Harris AL
    Exp Cell Biol; 1985; 53(1):1-8. PubMed ID: 3881300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of aromatase in breast tumors.
    Reed MJ
    Breast Cancer Res Treat; 1994; 30(1):7-17. PubMed ID: 7949206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma and urinary oestrogens in breast cancer patients on treatment with 4-hydroxyandrostenedione.
    Johannessen DC; Adlercreutz H; Fotsis T; Lønning PE
    Br J Cancer; 1993 Aug; 68(2):393-8. PubMed ID: 8135918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postmenopausal estrogen synthesis and metabolism: alterations caused by aromatase inhibitors used for the treatment of breast cancer.
    Lønning PE; Dowsett M; Powles TJ
    J Steroid Biochem; 1990 Mar; 35(3-4):355-66. PubMed ID: 2139151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steroid hormone profiles in women treated with aminoglutethimide for metastatic carcinoma of the breast.
    Samojlik E; Santen RJ; Kirschner MA; Ertel NH
    Cancer Res; 1982 Aug; 42(8 Suppl):3349s-3352s. PubMed ID: 7083199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.